Analysts Offer Insights on Healthcare Companies: LifeMD (LFMD) and Dexcom (DXCM)
Lake Street Maintains LifeMD(LFMD.US) With Buy Rating, Maintains Target Price $12
Mizuho Securities Maintains LifeMD(LFMD.US) With Hold Rating
Mizuho Securities Sticks to Its Hold Rating for LifeMD (LFMD)
Lake Street Initiates Coverage On LifeMD With Buy Rating, Announces Price Target of $12
LifeMD Analyst Ratings
Lake Street Starts Virtual Primary Care Provider LifeMD With a Buy
Lake Street Initiates LifeMD(LFMD.US) With Buy Rating, Announces Target Price $12
Mizuho Initiates Coverage On LifeMD With Neutral Rating, Announces Price Target of $7
Craig-Hallum Maintains LifeMD(LFMD.US) With Buy Rating
H.C. Wainwright Maintains LifeMD(LFMD.US) With Buy Rating, Maintains Target Price $12
LifeMD Analyst Ratings
Craig-Hallum Maintains LifeMD(LFMD.US) With Buy Rating, Announces Target Price $16
B.Riley Financial Maintains LifeMD(LFMD.US) With Buy Rating, Raises Target Price to $12
BTIG Maintains LifeMD(LFMD.US) With Buy Rating, Maintains Target Price $12
B.Riley Financial Maintains LifeMD(LFMD.US) With Buy Rating, Maintains Target Price $11
Craig-Hallum Maintains LifeMD(LFMD.US) With Buy Rating
Craig-Hallum Maintains LifeMD(LFMD.US) With Buy Rating
B.Riley Financial Maintains LifeMD(LFMD.US) With Buy Rating, Cuts Target Price to $11
LifeMD Analyst Ratings